Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer

摘要: Abstract The mechanism(s) by which weekly paclitaxel exerted more therapeutic efficacy than the triweekly schedule in relapsed breast cancer is still unclear. To assess rationale of cancer, pharmacokinetic and biochemical analyses were examined terms mean peak plasma concentration at 0 min (Cmax), 30 min, 24 h after finishing infusion, extracellular domain HER-2 response to treatment with paclitaxel. Twenty-five patients treated 1 infusion dose range from 40 mg/m(2) 80 studied. Eleven responded including 4 cases complete (CR) 7 partial (PR), while 14 did not respond 12 no change (NC) 2 progressive disease (PD). measured high-pressure liquid chromatography enzyme immunoassay, respectively. (Cmax) other peaks 10 3 mg/m(2), 60 compared proportion increase escalation, their tumor response. Further, levels 17 measured, also Cmax was 1.94, 2.18 1.54 microM, escalation intensity correlated nor In contrast, level responders higher that non-responders regimen(p=0.0512, Mann-Whitney's U-test). These results suggest associated intensity, rather protein may be a predictor cancer.